So, we had to quantify this evidence to show that it stemmed from the FDA approval and how to contain the risk
We excluded patients with cirrhotic liver, history of gall bladder, biliary disorders, pancreatic diseases, interrupted use of GLP-1RAs throughout the study period, and patients used other drugs with potential effects on the motility of biliary tracts such as cholecystokinin, motilin hormone, cholinomimetic agents like prostigmine, erythromycin, cisapride, cholystyramine, intravenous aminoacids, cholinergic agents like atropine, somatostatin, and progesterone, trimebutine, loperamide and ondansetron
GLP-1 Market Share, By Indication, 2025 (%) The obesity and weight management segment held a 28% share of the market in 2025 and is expected to grow at the fastest CAGR of 18.6% during the projection period
For traditional pairwise meta-analysis, the standardized mean difference (SMD) along with their 95% confidence intervals (Cls) were calculated for continuous variables